Application of Butorphanol versus Sufentanil in Multimode Analgesia via Patient Controlled Intravenous Analgesia After Hepatobiliary Surgery: A Retrospective Cohort Study
Xiaodong Xu,Yuan Tao,Yitian Yang,Jiaqiang Zhang,Mingyang Sun
DOI: https://doi.org/10.2147/dddt.s433136
IF: 4.3188
2023-12-20
Drug Design Development and Therapy
Abstract:Xiaodong Xu, &ast Yuan Tao, &ast Yitian Yang, Jiaqiang Zhang, Mingyang Sun Department of Anesthesiology and Perioperative Medicine, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, 450003, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jiaqiang Zhang; Mingyang Sun, Department of Anesthesiology and Perioperative Medicine, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, 450003, People's Republic of China, Tel +0 371 6558 0728, Email ; Purpose: We investigate the efficacy and safety of butorphanol in multimodal analgesia combined with dexmedetomidine and ketorolac via patient-controlled intravenous analgesia (PCIA) after hepatobiliary surgery, as compared with sufentanil. Patients and Methods: Postoperative follow-up data of hepatobiliary surgery patients in Henan Provincial People's Hospital from March 2018 to June 2021 were collected retrospectively and divided into butorphanol group (group B) or sufentanil group (group S) according to the postoperative intravenous controlled analgesia scheme. The baseline characteristics and surgical information of the two groups were matched through propensity score matching (PSM). Results: A total of 3437 patients were screened, and PSM yielded 1816 patients after matching, including 908 in the butorphanol group and 908 in the sufentanil group. Compared with group S, the incidence of moderate-to-severe pain on the first postoperative day and the second postoperative day was lower in group B during rest (3.2% vs 10.9%, P < 0.001; 1.2% vs 4.6%, P < 0.001), and during movement (7.0% vs 18.9%, P < 0.001; 2.6% vs 8.7%, P < 0.001). Patients receiving butorphanol had a lower morphine consumption (50mg vs 120mg, P < 0.001). The bolus attempts of an analgesic pump in group B were significantly lower than in group S (1 vs 2, P < 0.001). Postoperative hospital length of stay was shortened in group B (11d vs 12d, P =0.017). The occurrence of postoperative vomiting was lower in group B (1.4% vs 3.0%, P =0.025) than in group S. However, more patients in group B experienced dizziness (0.9% vs 0.1%, P =0.019). Conclusion: Compared with sufentanil, the application of butorphanol in multimodal analgesia combined with dexmedetomidine and ketorolac via PCIA ameliorated postoperative pain after hepatobiliary surgery, with reduced opioid consumption and shorter postoperative hospital length of stay. Keywords: patient controlled intravenous analgesia, butorphanol, sufentanil, propensity score matching Acute postoperative pain remains one of the most common challenges in patients undergoing hepatobiliary surgery. 1,2 Insufficient analgesia has been associated with increased sympathetic activation, immune suppression, higher risk of cardiovascular and respiratory systems, delayed recovery of gastrointestinal peristalsis function, and adverse psychological emotions. 3,4 If not well controlled in the initial stage, acute pain may result in peripheral and central sensitization, and evolve into chronic pain after surgery. 5–7 Therefore, adequate postoperative analgesia is fundamental and acts as a core principle in the context of the Enhanced Recovery After Surgery (ERAS) program. 8,9 Considering that pain patterns in patients receiving hepatobiliary surgery are multifactorial and differ from other procedures, effective multimodal analgesia with the combination of differing targeting pain pathways has been suggested to be the optimal pain management in abdominal surgery. 10,11 Current evidence emphasizes the growing interest in novel techniques, including intrathecal morphine, truncal nerve blocks, as well as emerging analgesics including esketamine, 5-HT 3 -antagonists, and so on. 2,12–16 However, opioids are still utilized as the first-line choice for perioperative pain management due to their powerful rapid-onset systematic analgesic effect. 17 Meanwhile, they could also induce a high incidence of opioid-related side effects, including delayed respiratory depression, nausea and vomiting, urinary retention, itching, dizziness, and so on. 4 Strategies to minimize opioid consumption, whilst optimizing patient comfort and postoperative recovery are of priority. Butorphanol, an opioid receptor agonist-antagonist, has been widely used in postoperative pain management recently. Butorphanol mainly acts on the κ receptors in the presynaptic and postsynaptic membranes of neurons in the central nervous system. By inhibiting adenylyl cyclase, it reduces the intracellular cyclic adenosi -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal